Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Toms primary responsibility is to support all aspects of trade and treasury operations. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. The market worked. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Jenna has a B.A. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Joey ONeill is an Investor Services Associate at RA Capital Management. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Harveys primary responsibility is to oversee all accounting related activities for the firm. Abhishek gained experience using data analytics to track and visualize patient testing in his most recent role at Blueprint Medicines. From time to time we may post specific open positions, but more often we will create positions for the right people. BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech RA Capital makes no guarantees as to their accuracy or completeness. Lorena Chen is a Fund Controller at RA Capital Management. Copyright 2023 Surperformance. Peter Pan Is The Real Villain: Disney Supports The Evil Peter Pan Theory Parents need to know that Peter Pan & Wendy takes on some of the weightier themes of J.M. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Founders GSAS Harvard Biotech Club TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. They will discuss the origins and history . In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Samuel Chowdhury is a Software Engineerat RA Capital Management. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. Tim received his A.B. Chris primary responsibility at RA Capital is to oversee the firms information technology program, including operations, development, and security. Ross Chikarmane is an Associate with the TechAtlas division of RA Capital Management. Bretts primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Tom has a BS in Physiological Sciences from University of California Los Angeles. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). In his career, Scott has worked to raise over $600 million in funding for ventures with which he has been directly involved as a founder or operating executive. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Vanderpump Rules' Peter Madrigal's Age. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Alex is an Associate with the TechAtlas division of RA Capital Management. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Eric is the Chief Compliance Officer at RA Capital Management. Peter Kolchinsky on Twitter Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. In his Venture role, Mario is focusing on early-stage investment and company creation. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Josh is a Senior Research Assistant at RA Capital Management. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Chris Morrison is an Editor at RA Capital Management. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. Sarah Reed is the General Counsel at RA Capital Management. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Emily Greenis a Visual Identity Designer at RA Capital Management. Peter Kolchinsky Number of IPOs: 18. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Let's Throw a Patent-Burning Party | by Peter Kolchinsky - Medium Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Robert received his BS in mechanical engineering from the University of Houston. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Phi Thach is an Executive Assistant at RA Capital Management. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). She previously worked as a Finance Associate at the MFA Companies. BioVentures. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. Brett Scheller is a Compliance Officer at RA Capital Management. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Brian is a IT Operations Manager at RA Capital Management. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. He holds a MS from Northeastern University and a BA from Hamilton College. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Michael is the Chief Financial Officer at RA Capital Management. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Laura previously worked at WinterWyman where she served as a Senior Associate. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. EXCLUSIVE : Robert Morgan's Talaria . While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Kyle Teamey joins RA Capital as a Managing Partner, Planetary Health. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. Megan has a BS in Microbiology & Cell Science from University of Florida. Special Projects Operations Manager/Chief of Staff. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. Laura Stoppel is a Principal on the Investment Team at RA Capital Management. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst All rights reserved. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Jacqueline is an Associate, Strategic Finance at RA Capital Management. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Michael Calore is the Director of Investor Relations at RA Capital Management. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. He continues advising both in a consultant capacity. Kriti holds a B.S. In this role, Emily works closely with senior leaders, Venture Partners and Managing Directors within the Venture Team at RA Capital and within RAVen. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. Christy is a Senior Associate with the TechAtlas division of RA Capital Management.
44 Caliber Black Powder Revolver Made In Italy Value,
Articles P